이상반응 보고

VAERS ID 1626008
성별 여성
나이
주 코드 NJ
제약회사 MODERNA
로트 번호
예방접종 횟수 1
접종일 2020-12-24
발병일 2020-12-01
상태
증상
  • 피로(Fatigue)
  • 사지의 통증(Pain in extremity)
  • 두통(Headache)
  • 현기증(Dizziness)
  • 통증(Pain)
  • 핫 플러시(Hot flush)
  • 추워요(Feeling cold)
  • 모유 수유 중 산모 노출(Maternal exposure during breast feeding)
  • 수유 장애(Lactation disorder)

이환 중 질병

지병

Medical History/Concurrent Conditions: COVID-19 (In her seventh month of pregnancy)

기타 의료

이전 예방접종

알레르기

임상 검사

증상 상세

Unable to produce milk; headache; tiredness; woke up with dizziness; arm was in pain and sitll sore; body aches; I was breast feeding 5 month old baby boy; hot and cold flashes; hot and cold flashes; A spontaneous report was received from a 42 year old, female patient who received Moderna's COVID-19 vaccine (mRNA-1273) and experienced arm in pain, dizziness, body aches, hot & cold flashes, headache, breastfeeding my 5 month old baby boy, unable to produce milk and still very tired.
The patient's medical history included Covid-19.
No relevant concomitant medications were reported.
On 24 Dec 2020, at 9:30 am – 10am, the patient received their first of two planned doses of mRNA-1273 intramuscularly (lot number unknown) in her left arm for prophylaxis of COVID-19 infection.
On 25 Dec 2020, at midnight, the patient stated that her arm was in pain and that she woke up with dizziness, body aches.
She experienced hot and cold flashes (3 - 4 days after) and headache.
Treatment included paracetamol.
The patient noted she was still experiencing dizziness and headache.
The body aches were coming and going.
Her arm was still sore.
She was breastfeeding her 5-month-old baby boy, but was unable to produce milk at the time of this report, and was still very tired.
Action taken with mRNA-1273 vaccine was not provided.
The events dizziness, headache, body aches, arm pain and sore, and still very tired were still ongoing and the outcome hot & cold flashes, breastfeeding her 5 month old baby boy, and unable to produce milk were unknown.
; Reporter's Comments: This is a case of product exposure during breastfeeding with some associated AEs.
Patient will continue to be contacted for further monitoring of AEs.